GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » Float Percentage Of Total Shares Outstanding

Genetic Analysis AS (FRA:8V8) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genetic Analysis AS's float shares is 0.00 Mil. Genetic Analysis AS's total shares outstanding is 42.16 Mil. Genetic Analysis AS's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genetic Analysis AS's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genetic Analysis AS's Institutional Ownership is 0.00%.


Genetic Analysis AS Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Genetic Analysis AS's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/42.16
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS (FRA:8V8) Business Description

Industry
Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines